For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Editas Medicine, Inc.

USPTO Granted Patents = 53

CIPO Patents = 1

EPO Patents = 20

Trademarks = 7

Forward Citations = 194

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

David A Bumcrot (14 out of 54 patents)

Morgan Lee Maeder (14 out of 14 patents)

Hariharan Jayaram (12 out of 12 patents)

4. Ari E Friedland (11 out of 12 patents)

5. Barrett Ethan Steinberg (10 out of 23 patents)

6. Cecilia Cotta-Ramusino (8 out of 8 patents)

7. Shen Shen (7 out of 8 patents)

8. Jennifer Leah Gori (5 out of 7 patents)

9. Feng Zhang (4 out of 185 patents)

10. Deborah Palestrant (4 out of 8 patents)

11. Jordi Mata-Fink (4 out of 26 patents)

12. Edgardo Rodriguez (4 out of 9 patents)

13. Alexis Borisy (4 out of 14 patents)

14. John Zuris (4 out of 14 patents)

15. Penrose O'Donnell (4 out of 4 patents)

Core Competencies:

CRISPR-Cas9

Gene Editing

Immunotherapy

Nuclease Cleavage

Homology Directed Repair

Guide RNA

Exon-Skipping

Chromosomal Rearrangements

Cancer Treatment

Retinal Dystrophy

Hemoglobinopathies

Cystic Fibrosis

53 patents: Sort by Forward Citations

1. 12698489 - METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY (2026-08-04),

2. 12545912 - CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa (2026-02-10),

3. 12460231 - Crispr/CAS-related methods and compositions for treating primary open angle glaucoma (2025-11-04),

4. 12359223 - Systems and methods for modulating chromosomal rearrangements (2025-07-15),

5. 12338436 - Synthetic guide molecules, compositions and methods relating thereto (2025-06-24),

6. 12331328 - CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome (2025-06-17),

7. 12325854 - Crispr-CPF1-related methods, compositions and components for cancer immunotherapy (2025-06-10),

8. 12297466 - Engineered Cas9 nucleases (2025-05-13),

9. 12286727 - Assessing nuclease cleavage (2025-04-29),

10. 12264331 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2025-04-01),

11. 12234449 - CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) (2025-02-25),

12. 12214055 - Systems and methods for treating hyper-igm syndrome (2025-02-04),

13. 12201699 - Compositions and methods for promoting homology directed repair (2025-01-21),

14. 12110545 - Methods of assessing nuclease cleavage (2024-10-08),

15. 12049651 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2024-07-30),

Editas Medicine, Inc. is a leading genome editing company focused on translating the power and promise of CRISPR technology into a broad class of transformative medicines to treat patients suffering from serious diseases. With a combination of deep scientific expertise and unmatched experience in genome editing, Editas Medicine is advancing a robust pipeline of potential therapies for genetically defined diseases.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Editas Medicine, Inc.

53 Patents

#49 in Cambridge, MA

#377 in Massachusetts

#6,661 in US

#13,309 in the World

Cambridge, MA, United States of America

Editas Medicine, Inc.

Forward Citations = 194

75 inventors:

David A Bumcrot (14 out of 54 patents)

Morgan Lee Maeder (14 out of 14 patents)

Hariharan Jayaram (12 out of 12 patents)

4. Ari E Friedland (11 out of 12 patents)

5. Barrett Ethan Steinberg (10 out of 23 patents)

Please report any incorrect information to [email protected]

Loading…